Asian Spectator

Eisai's Discovery Research on Multikinase Inhibitor Lenvatinib Honored with PSJ Award for Drug Research and Development '20

  • Written by ACN Newswire - Press Releases

Eisai's Discovery Research on Multikinase Inhibitor Lenvatinib Honored with PSJ Award for Drug Research and Development '20

TOKYO, Mar 25, 2020 - (JCN Newswire) - Eisai Co., Ltd. has announced that drug discovery research conducted on lenvatinib mesylate (brand name: LENVIMA, lenvatinib), the orally available multikinase inhibitor discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development '20 by the PSJ.The PSJ Award for Drug Research and Development is one of a series of awards presented by the PSJ and is dedicated to researchers who have conducted outstanding research work that has contributed to medicine through the innovative development of a pharmaceutical drug or applicable technology related to the pharmaceutical sciences. Award recipients are evaluated by the PSJ based on the ingenuity of the research itself as well as the effectiveness and safety of the related pharmaceutical product(s) or the innovativeness of the related medical treatment or treatment technology. The PSJ Award for Drug Research and Development was introduced by the PSJ in 1988, with Eisai previously receiving the award for drug discovery research in 1998 on donepezil hydrochloride, an Alzheimer's disease treatment, and in 2013 on eribulin mesylate, an anti-cancer agent.The reasons for the selection of this discovery research for the award are outlined by the PSJ as follows. First, Eisai researchers created lenvatinib as a new type of kinase inhibitor with type V binding mode through a creation of the original screening models reflecting human disease and refined optimization of leading compounds. Furthermore, lenvatinib mesylate demonstrated antitumor activity against various types of cancer in clinical trials, which was accomplished with strategic application of drug properties to selectively inhibit kinases associated with tumor growth and pathogenic angiogenesis. At the time of application for the award, lenvatinib mesylate received approval as a treatment for refractory thyroid cancer, unresectable hepatocellular carcinoma, and advanced renal cell carcinoma. Finally, lenvatinib discovery research realized an innovative drug that received the Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) and holds high potential to contribute to anticancer therapy worldwide.Currently, lenvatinib has been approved as a treatment for refractory thyroid cancer in more than 60 countries including Japan, the United States, and in Europe; as a treatment for unresectable hepatocellular carcinoma in more than 55 countries including Japan, the United States, in Europe, China and in Asia; as well as in combination with everolimus as a treatment for advanced renal cell carcinoma (second-line) in more than 50 countries including the United States, in Europe and in Asia. Additionally, it is also approved in the combination treatment of lenvatinib plus KEYTRUDA (pembrolizumab) for advanced endometrial carcinoma in the United States, Australia, and Canada.Eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards curing cancer. Eisai is committed to exploring the potential clinical benefits of lenvatinib and aims to make continuous efforts to meet the diversified needs of and increase the benefits provided to patients with cancer, their families, and healthcare professionals.

About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

SANNE Strengthens Its Corporate Services Offering With New Sen...

SAINT HELIER, Jersey, July 6, 2020 /PRNewswire-AsiaNet/ -- SANNE, a leading global provider of alternative asset and corporate services has appointed Brijesh Patel as Global Head of Corporat...

Real Madrid CF And Legends Announce Groundbreaking Global Omni...

MADRID, July 7, 2020 /PRNewswire-AsiaNet/ -- -- Comprehensive Partnership Spans E-Commerce, Retail at Santiago Bernabeu Stadium, and Official Real Madrid Stores ---- Real Madrid and Legends ...

GSB Gold Standard Banking, Josip Heit and SPREE FLUG in Times of Coronavirus

HAMBURG, GERMANY - NEWSAKTUELL - 6 July 2020 - In the coronavirus pandemic, job cuts, such as those currently at the aircraft manufacturer Airbus, are hitting the Federal Republic ...

Toyota Reproduces and Sells Spare Parts for 2000GT

Toyota City, Japan, Jul 6, 2020 - (JCN Newswire) - TOYOTA GAZOO Racing (hereafter TGR) announces that it will reproduce spare parts for Toyota 2000GT as GR Heritage Parts Project, and will ...

CERtified - Cryptocurrency Exchanges Security Standard by Hacken

KYIV, Ukraine, July 6, 2020/PRNewswire-AsiaNet/-- The cybersecurity of cryptocurrency exchanges is paramount in today's increasingly digital world. These platforms are responsible for large ...

VIET CAPITAL BANK and 7-ELEVEN VIETNAM Launch JCB CARD

Ho Chi Minh and Tokyo, Jul 6, 2020 - (ACN Newswire) - Viet Capital Commercial Joint Stock Bank (Viet Capital Bank), a major commercial bank in Vietnam, Seven System Viet Nam Jsc (7-Eleven V...

Cosmopack and Cosmoprof Asia 2020 Will Be Held under One Roof

HONG KONG, July 6, 2020 /PRNewswire-AsiaNet/ -- Asia's Leading International B2B Beauty Show Creates Industry Inclusivity Joint organisers BolognaFiere Group and Informa Markets have decided...

Fujitsu Embarks Towards 'New Normal', Redefining Working Styles for its Japan Offices

TOKYO, Jul 6, 2020 - (JCN Newswire) - Fujitsu today announced that it will further accelerate its shift to becoming a Digital Transformation (DX) company with an ambitious campaign to redef...

Two hot news of Dongguan reflect the city's inclusiveness and ...

DONGGUAN, China, July 6, 2020 /Xinhua-AsiaNet/-- Recently, two local news about China's Dongguan city have gained wide attention from the Chinese media. One is that a message left by a migra...

Eisai to Launch In-House Developed New Anti-insomnia Drug Dayvigo (Lemborexant) with Indication for Insomnia in Japan

TOKYO, Jul 6, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has launched its in-house-discovered and developed orexin receptor antagonist DAYVIGO? 2.5 mg, 5 mg, 10 mg tabl...

Adyen Expands Acquiring Capabilities to Malaysia

Adyen launches its acquiring solution in Malaysia to help local businesses achieve higher authorization rates, better customer experience, and deeper data insights as the Malaysian market tr...

Eisai: New Fine Granule Formulation of Anti-epileptic Drug Fycompa Launched in Japan

TOKYO, Jul 6, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has launched a new fine granule formulation of its in-house-discovered antiepileptic drug (AED) Fycompa (peramp...

VIB 2020 AGM results announcement: Journey to a large scale an...

HANOI, Vietnam, July 6, 2020 /PRNewswire-AsiaNet/-- The Annual General Meeting (AGM) of Vietnam International Bank (VIB) was held on June 30, 2020 in HoChiMinh City. All the reports and prop...

DHL positioned as a Leader in the 2020 Gartner Magic Quadrant for Third-Party Logistics, Worldwide

“Dialog and proximity to our customers help us react quickly to changing market conditions, especially in times of the Corona crisis,” said Oscar de Bok, CEO of DHL Supply Chain...

JGA North is Ready for Service

SINGAPORE, Jul 6, 2020 - (JCN Newswire) - RTI Connectivity Pte. Ltd. (RTI) and NEC Corporation (NEC) jointly announced the successful completion of the Japan-Guam-Australia North Cable Syst...

Hi-Chew Goes Bold with Expanded Marketing Campaign

SYDNEY, July 6, 2020 /PRNewswire-AsiaNet/-- Morinaga Asia Pacific is launching an expanded marketing campaign to support retail sales of Hi-Chew fruit chews in Australia and New Zealand. Log...

Aichi Cancer Center and NEC Launch Joint Research on Fundamental Study Aimed at Advanced Cancer Immunotherapy

TOKYO, Jul 6, 2020 - (JCN Newswire) - Aichi Cancer Center(1) and NEC Corporation (NEC; 6701) today announced the launch of fundamental research aiming to realize the promise of advanced per...

Infoblox Appoints George Chang as Vice President of Sales to A...

SINGAPORE, July 6, 2020 /PRNewswire-AsiaNet/-- -- The company doubles down on senior hires in the region to drive customer growthInfoblox Inc., the leader in Secure Cloud-Managed Network Ser...

'PENINSULA' will have a 'TwitterBlueroom LIVE Q A' session to interact with global fans on July 9 KST, ahead of its premiere!

'Train to Busan' sequel 'PENINSULA' is ready to create global phenomenon! 'Gang Dongwon', 'Lee Junghyun', and Director 'Yeon Sangho' lead conversations'PENINSULA' is the 1st case of K-m...



News Company Media Core

Content & Technology Connecting Global Audiences

More Information - Less Opinion